- Home
- SLVM vs GENB Comparison
SLVM vs GENB Comparison
Compare SLVM & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLVM | GENB |
|---|---|---|
| Founded | 1898 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLVM | GENB |
|---|---|---|
| Price | $38.58 | $13.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $54.00 | $23.20 |
| AVG Volume (30 Days) | 312.4K | ★ 1.0M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,351,000,000.00 | N/A |
| Revenue This Year | $0.93 | N/A |
| Revenue Next Year | $1.54 | $16.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.53 | $11.00 |
| 52 Week High | $56.80 | $18.18 |
Technical Indicators
Market Signals| Indicator | SLVM | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 40.11 |
| Support Level | $36.87 | $11.73 |
| Resistance Level | $43.60 | $13.76 |
| Average True Range (ATR) | 1.48 | 1.02 |
| MACD | 0.04 | -0.39 |
| Stochastic Oscillator | 43.81 | 9.24 |
Price Performance
Historical ComparisonAbout SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.